Growth Through Acquisition Custopharm was acquired by Hikma Pharmaceuticals for $375 million in late 2021, indicating strong market interest and growth potential within the sterile injectable segment. This acquisition highlights opportunities for sales expansion into larger pharmaceutical portfolios and distribution channels.

Early Commercial Stage Despite its relatively small employee base of 11-50, Custopharm has developed over 30 products and serves more than 100 clients, signaling rapid growth and an expanding product pipeline that can be leveraged for targeted business development and partnership opportunities.

Focus on High Barrier Products Custopharm specializes in high barrier, generic injectable drugs aimed at making therapies more accessible, which aligns with current market trends favoring complex generics and biosimilars—potential avenues for expanding sales into specialty markets.

Strategic Industry Positioning Partnered with Water Street Healthcare Partners since 2015, Custopharm benefits from strategic investment and industry expertise, presenting opportunities for collaborative ventures, licensing deals, and expanding its customer base within the pharmaceutical manufacturing sector.

Competitive Market Presence Operating alongside large pharma competitors like Hikma, Amneal, and Teva with comparable product offerings, Custopharm presents opportunities to target niche segments, specialty hospitals, and global markets seeking reliable sterile injectable suppliers.